Melanoma adjuvant therapy.

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Cutaneous melanoma recurrence risk varies based on tumor depth, ulceration, mitotic rate, and metastasis.
• Adjuvant therapy is crucial for high-risk melanoma to eliminate micrometastases and prevent mortality.
• Interferon-α has historically improved relapse-free and overall survival in melanoma patients.

Purpose of the Study:

• To review standard of care adjuvant melanoma therapy.
• To discuss completed, ongoing, and planned clinical trials for adjuvant melanoma treatment.
• To highlight advances in understanding melanoma biology and immunology for novel therapeutic targets.

Main Methods:

• Review of randomized clinical trials (e.g., E1684, E1694).
• Analysis of data on interferon-α efficacy.
• Examination of emerging adjuvant therapies targeting melanoma molecular biology and host immunology.

Main Results:

• High-dose interferon-α demonstrated significant relapse-free and overall survival benefits compared to observation and GMK vaccine.
• Novel targeted agents show unprecedented results in metastatic melanoma and are being tested in the adjuvant setting.
• Recent data suggest a significant clinical impact of adjuvant ipilimumab.

Conclusions:

• Adjuvant therapy is essential for high-risk melanoma patients to improve cure rates.
• Interferon-α remains a standard treatment, though newer immunotherapies like ipilimumab offer significant promise.
• Ongoing and future clinical trials are critical for advancing adjuvant melanoma treatment strategies.